Chemoprevention of gastric cancer: current status

被引:0
|
作者
Xia, HHX [1 ]
Wong, BCY [1 ]
Lam, SK [1 ]
机构
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
关键词
chemoprevention; gastric cancer; Helicobacter pylori;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The development of gastric cancer is a multi-factor process. In addition to genetic factors, environmental factors including smoking, low gastric acidity, excessive intake of salt or salty food and low consumption of fresh fruits and vegetables all contribute to the development of gastric cancer. Of particular interest, epidemiological and experimental studies have demonstrated that Helicobacter pylori (H. pylori) infection is causally linked to gastric cancer. Most studies using micronutrient supplementation have failed to demonstrate any preventive effect against the development of gastric cancer. The use of non-steroidal anti-inflammatory drugs has been consistently observed to protect against the development of gastric cancer. Recently, eradication of H. pylori infection by a chemopreventative approach is being studied in a number of trials. Studies using precancerous lesions as an end point of the treatment have produced conflicting and mostly negative results. Trials using cancer as an end point are being cautiously carried out in high-risk populations, and will provide the definitive answer to this important question. In the end, vaccination may be proven to be the optimal strategy in human for the management of H. pylori infection and prevention of gastric cancer.
引用
收藏
页码:5 / 10
页数:6
相关论文
共 50 条
  • [21] Chemoprevention of Colon Cancer: Current Status and Future Prospects
    David M. Gustin
    Dean E. Brenner
    Cancer and Metastasis Reviews, 2002, 21 : 323 - 348
  • [22] The current status of breast cancer chemoprevention: A star is born
    Morrow, Monica
    Jordan, V. Craig
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 95 (01) : 4 - 5
  • [23] Prostate cancer chemoprevention: Current status and future prospects
    Gupta, Sanjay
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (03) : 369 - 376
  • [24] Gastric Cancer Chemoprevention
    Nardone, G.
    Compare, D.
    Ferrara, G.
    Nardone, O. M.
    Sanduzzi-Zamparelli, M.
    Sannino, A.
    Sica, M.
    Rocco, A.
    9TH INTERNATIONAL GASTRIC CANCER CONGRESS (IGCC 2011): A GATE TO THE FUTURE OF GASTRIC CANCER TREATMENT, 2011, : 47 - 52
  • [25] Chemoprevention of gastric cancer
    Leung, Wai K.
    Sung, Joseph J. Y.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2006, 18 (08) : 867 - 871
  • [26] Chemoprevention for gastric cancer
    Ford, Alexander C.
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2011, 25 (4-5) : 581 - 592
  • [27] The current status of chemoprevention in FAP
    M. H. Wallace
    P. M. Lynch
    Familial Cancer, 2006, 5 : 289 - 294
  • [28] The current status of chemoprevention in FAP
    Wallace, M. H.
    Lynch, P. M.
    FAMILIAL CANCER, 2006, 5 (03) : 289 - 294
  • [29] CURRENT STATUS OF CHEMOPREVENTION TRIALS AT THE NATIONAL-CANCER-INSTITUTE
    NIXON, DW
    CANCER INVESTIGATION, 1990, 8 (06) : 625 - 627
  • [30] Current status and future perspectives of chemoprevention in head and neck cancer
    Klass, Carmen M.
    Shin, Dong M.
    CURRENT CANCER DRUG TARGETS, 2007, 7 (07) : 623 - 632